Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Hannah Johnston, Abigail Sneider, Tuula Pera, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Mariam Nawas, Anand Patel, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Olatoyosi Odenike, Richard Larson, Caner Saygin, Wendy Stock, Christopher Daugherty

Blood (2025) 146 (Supplement 1): 6382.

https://doi.org/10.1182/blood-2025-6382

Published: 2025

Journal Articles

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Chadi Nabhan, Jeremy Abramson, Tyler Fraum, Ajay Nooka, Gary Schiller, David Schuster, Michael Thirman, Kayla Haines, Erin Shonkwiler, Mohammad Jahanzeb

Blood (2025) 146 (Supplement 1): 4359.

https://doi.org/10.1182/blood-2025-4359

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

Eytan M. Stein, Ibrahim Aldoss, John F. DiPersio, Richard M. Stone, Martha L. Arellano, Galit Rosen, Michael L. Meyers, Yifan Huang, Steve Smith, Rebecca G. Bagley, Michael Thirman, Manish R. Patel, Ghayas C. Issa

Blood (2021) 138 (Supplement 1): 699.

https://doi.org/10.1182/blood-2021-146944

Published: 2021

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease

Hongtao Liu, MD, PhD, Greg Koval, MS, Greg Malnassy, MS, Pamela Ihonor, MS, Hui Liu, MS, Roger Luo, PhD, Amittha Wickrema, PhD, Steven Dowdy, PhD, Michael Thirman, MD, Koen van Besien, MD, Wendy Stock, MD

Blood (2010) 116 (21): 3921.

https://doi.org/10.1182/blood.V116.21.3921.3921

Published: 2010

Journal Articles

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Sarah Larson, MD, Nicholas Campbell, MD, Dezheng Huo, PhD, Andrew Artz, MD, MS, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, MD, Lucy A Godley, MD, PhD, Elizabeth Shima Rich, MD, PhD, Michael Thirman, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2009) 114 (22): 1048.

https://doi.org/10.1182/blood.V114.22.1048.1048

Published: 2009

Journal Articles

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Vaishalee P. Kenkre, MD, Sarah Horowitz, Richard A. Larson, MD, Andrew Artz, MD, MS, Elizabeth Shima Rich, MD, PhD, Yanming Zhang, M.D., M.S., Michelle M. Le Beau, PhD, Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Michael Thirman, MD, Koen van Besien, MD, Wendy Stock, MD

Blood (2009) 114 (22): 3395.

https://doi.org/10.1182/blood.V114.22.3395.3395

Published: 2009

Journal Articles

Kinetic Analysis of the Interactions Between the Different ELL and EAF Proteins Involved in Acute Myeloid Leukemia

Nimisha Sharma, Elena Solomaha, Federico Simone, Michael Thirman

Blood (2008) 112 (11): 3116.

https://doi.org/10.1182/blood.V112.11.3116.3116

Published: 2008

Journal Articles

Autoregulation of MEIS1 through a Distal Enhancer in Acute Leukemia

Qianfei Wang, PhD, Jingfang Dong, PhD, Ryan Mattison, MD, Shyam Prabhakar, PhD, Fabio Eiji Arimura, Joseph Kaberlein, Chong-zhi Wang, PhD, Qianben Wang, PhD, Marcelo Nobrega, PhD, Michael Thirman, MD

Blood (2008) 112 (11): 745.

https://doi.org/10.1182/blood.V112.11.745.745

Published: 2008

Journal Articles

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, MS, Wendy Stock, MD, Sonali M. Smith, MD, Christopher Daugherty, MD, Lucy Godley, MD, PhD, Todd Zimmerman, MD, Olatoyosi M. Odenike, MD, Michael Thirman, MD, Elizabeth Rich, MD, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2004) 104 (11): 1145.

https://doi.org/10.1182/blood.V104.11.1145.1145

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Kinetic Analysis of the Interactions Between the Different ELL and EAF Proteins Involved in Acute Myeloid Leukemia

Autoregulation of MEIS1 through a Distal Enhancer in Acute Leukemia

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only